Loading...
•
Jun 30, 2023
Fulcrum Therapeutics Q2 2023 Earnings Report
Reported financial results for the second quarter of 2023 and provided a business update.
Key Takeaways
Fulcrum Therapeutics reported its Q2 2023 financial results, with key highlights including the closure of screening for the Phase 3 REACH trial of losmapimod and ongoing interactions with the FDA to resolve the clinical hold for FTX-6058. The company's cash position remains strong, expected to fund operations into mid-2025.
Screening closed for the Phase 3 REACH pivotal trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD).
Topline data for REACH is expected in the fourth quarter of 2024.
Interactions are ongoing with the FDA to resolve the clinical hold for FTX-6058 in sickle cell disease (SCD).
Alan A. Musso was appointed as chief financial officer.
Fulcrum Therapeutics
Fulcrum Therapeutics
Forward Guidance
Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into mid-2025.